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Introduction: Age and gender may influence the incidence of aortic regurgitation (AR) and its severity. 
Significant aortic regurgitation (sAR) is often treated surgically especially when symptomatic or when 
systolic function declines.1 The aim of this study was to evaluate the outcomes in patients with sAR 
according to treatment strategy, age and gender differences in our study population. 
Patients and Methods: In this retrospective descriptive single-centre study an overall of 107 patients 
(22 female, 85 male) with significant AR in the last 5 years were analyzed. Patients were treated ac-
cording to valid recommendations, surgically (SUR) or conservatively (CON), except for 5 patients who 
refused surgery. Baseline and follow up (FU) data (AR severity, left ventricle ejection fraction (LVEF), 
ascending aorta diameter (AA), treatment, comorbidities and major adverse cardiovascular events 
(MACE) during FU), from documented medical history and digital imaging data were collected and 
analysed. Additional sub-analysis was performed according to sex and age differences (above vs. be-
low the age of 50). For statistical analysis a Chi-Square test was used. 
Results: In the overall study population, during an average FU of 3.8 years, 16 patients (15%) developed 
MACE with no statistically significant difference between gender (p=0.846). Forty-six (43%) patients 
were surgically treated (87% male, 13% female) and 61 (54%) conservatively. LVEF did not worsen in FU 
period (54.1%, vs. 53.8%). In SUR, median age was 54 years, severe AR was present in 93%, incidence of 
MACE was 21.7%, 80.4% patients were symptomatic and 14.5% had dilatation of AA more than 50 mm. 
In CON, MACE was present in 9.8% during FU (p=0.87), median age was 64 years. Moderate AR (48% vs 
6.5%) and AA from 40-49 mm (80 vs 35%) was present more frequently as well as arterial hypertension 
(82 vs 70%) and chronic renal disease (23.2 vs 16.6%). The incidence of MACE was not found to be age-
related (p=0.426). 
Conclusion: In patients with sAR treated by either surgery or medication therapy only, during 3.8 years 
of FU, LVEF remained unchanged, while incidence of MACE was not found to be related to treatment 
strategy nor gender. In surgically treated patients, as expected, AR was more severe and AA was more 
dilated, while neither age nor gender had an impact on the incidence of MACE.
